APA (7th ed.) Citation

Li, Z., Zhang, F., Jin, X., & Zhuang, J. Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab. BMC.

Chicago Style (17th ed.) Citation

Li, Ziping, Fujing Zhang, Xianghong Jin, and Junling Zhuang. Elevated LIF and JAK-STAT Activation Drive Severe COVID-19 in Myeloma Patients Receiving the BCMA-CD3 Bispecific Antibody Elranatamab. BMC.

MLA (9th ed.) Citation

Li, Ziping, et al. Elevated LIF and JAK-STAT Activation Drive Severe COVID-19 in Myeloma Patients Receiving the BCMA-CD3 Bispecific Antibody Elranatamab. BMC.